A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma
Abstract
null null Background null Recurrent/metastatic adenoid cystic carcinoma (ACC) is an incurable disease with no standard treatments. The majority of ACCs express the oncogenic transcription factor MYB (also c-myb), often in the context of a MYB gene rearrangement. This phase II trial of the tyrosine kinase inhibitor (TKI) axitinib (Pfizer) tested the hypothesis that targeting pathways activated by MYB can be therapeutically effective for ACC. null...
Paper Details
Title
A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma
Published Date
Oct 1, 2016
Journal
Volume
27
Issue
10
Pages
1902 - 1908
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History